Novel anti-somatostatin receptor 2 antibody-drug conjugate for neuroendocrine cancer therapy
Y. Si, S. Kim, R. Guenter, J. Ou, Y. Lu, K. Chen, J. Zhang, J. Whitt, A. M. Carter, J. A. Bibb, J. M. Markert, R. Jaskula-Sztul, L. Zhou, H. Chen, X. Liu
This study develops an anti-somatostatin receptor 2 antibody-drug conjugate (ADC) that effectively targets and kills neuroendocrine tumors with minimal toxicity.
bioRxiv · Nov 18, 2019 · PreprintBioengineering